Company profile for Opna Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP) and a diversified pipeline of validated oncology assets acquired from Plexxikon. The Opna team has a proven track record of scient...
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP) and a diversified pipeline of validated oncology assets acquired from Plexxikon. The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. In addition to its discovery-stage FMRP program.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Route de la Corniche 6 1066 Epalinges
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251104080483/en/Opna-Bio-Announces-2025-ASH-Presentations-Highlighting-Preclinical-Data-from-Novel-Protein-Degrader-Program-and-Updated-Interim-Data-from-Phase-1-Combination-Study-of-OPN-2853-with-Ruxolitinib-in-Advanced-Myelofibrosis

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20250212175926/en

BUSINESSWIRE
12 Feb 2025

https://www.businesswire.com/news/home/20241209262691/en

BUSINESSWIRE
09 Dec 2024

https://www.businesswire.com/news/home/20241113176172/en

BUSINESSWIRE
13 Nov 2024

https://www.businesswire.com/news/home/20240826690075/en

BUSINESSWIRE
26 Aug 2024

https://www.businesswire.com/news/home/20240410101743/en

BUSINESSWIRE
10 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty